The development of TKIs a decade ago revolutionized the treatment of CML. These medications (Gleevec, Sprycel, Tasigna, Bosulif and Iclusig) all work to inhibit the proliferation of leukemic cells. In some people, the disease may be so well suppressed that it amounts to a cure...
Life with chronic myelogenous leukemia changed a decade ago with what has been called the TKI revolution. The tyrosine kinase inhibitor (TKI) medications changed not only how CML is treated, but people’s expectations of what can be achieved.
While these standards were being developed, new laboratory techniques were enabling even more sensitive PCR testing for BCR-ABL transcripts. This opened up a new world beyond MMR – to a 4-log reduction, a 4.5-log reduction, and even a 5-log reduction.
TKIs are used in CML to suppress the abnormal signalling that promotes uncontrolled proliferation of white blood cells. How effective a given medication is can be determined with a blood test that determines the amount of signalling molecules (called BCR-ABL transcripts).
Report on EHA 2014 – Part 1: There are several large databases worldwide that track people with CML. One of the larger ones is maintained by EUTOS (European Treatment and Outcome Study), which collects information from 27 countries.